IN8bio, Inc.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. Its DeltEx platform supports allogeneic and autologous cell therapies, genetically modified and induced pluripotent stem cell-derived cells, and T… From the company’s description.
In fiscal 2025, IN8bio, Inc. reported a net loss of $19.44M. Operations used $12.71M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What IN8bio, Inc. does
In the company’s own words
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. Its DeltEx platform supports allogeneic and autologous cell therapies, genetically modified and induced pluripotent stem cell-derived cells, and T cell engagers designed to activate gamma-delta T cells. The company’s clinical programs include INB-100, a donor-derived cell therapy being studied in patients with high-risk leukemia undergoing stem cell transplantation, and INB-200 and INB-400, genetically modified therapies studied in newly diagnosed glioblastoma. INB-619 is a preclinical CD19-targeted T cell engager being developed for potential use in B cell-driven autoimmune diseases. Other preclinical programs include INB-300 and INB-500. IN8bio’s product candidates are wholly owned, and its manufacturing approach includes collaborators and potential contract manufacturers. The company operates as a clinical-stage developer and has not generated product sales. Its website is www.in8bio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1740279
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns IN8bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · IN8bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do IN8bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of IN8bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in IN8bio, Inc.'s last four quarterly filings that the numbers alone won't show?”